| Not Yet Recruiting | A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN) Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 3 | 2026-04-01 |
| Not Yet Recruiting | A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-positive Breast Cancer | Phase 3 | 2026-04-01 |
| Not Yet Recruiting | A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Ti Extensive-stage Small-cell Lung Cancer | Phase 3 | 2026-04-01 |
| Not Yet Recruiting | A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia | Phase 2 / Phase 3 | 2026-03-01 |
| Recruiting | A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metast Non-squamous Non-small Cell Lung Cancer | Phase 2 | 2026-02-03 |
| Recruiting | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tu Gastrointestinal Tumors, Solid Tumors | Phase 1 | 2026-01-12 |
| Recruiting | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Head and Neck Squamous Cell Carcinoma, Solid Tumor | Phase 1 | 2025-12-10 |
| Recruiting | A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Canc Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | 2025-12-10 |
| Not Yet Recruiting | A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancie Multiple Myeloma, Hematologic Malignancies | Phase 1 | 2025-12-01 |
| Recruiting | A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors Gastrointestinal Tumors, Solid Tumors | Phase 1 | 2025-11-14 |
| Recruiting | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Non Small Cell Lung Cancer, Solid Tumor | Phase 1 | 2025-11-11 |
| Recruiting | A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Non-squamous Non-small Cell Lung Cancer | Phase 3 | 2025-09-29 |
| Recruiting | A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanc Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 3 | 2025-09-24 |
| Recruiting | A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Cervical Cancer, Endometrial Cancer | Phase 2 | 2025-08-21 |
| Recruiting | A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | Phase 3 | 2025-08-04 |
| Recruiting | A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Non-small Cell Lung Cancer, Solid Tumor | Phase 1 | 2025-07-30 |
| Recruiting | A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer Renal Cancer | Phase 2 | 2025-07-28 |
| Recruiting | A Study of BL-B01D1 Combined With Lenvatinib in Patients With Advanced Hepatocellular Carcinoma Advanced Hepatocellular Carcinoma | Phase 2 | 2025-06-24 |
| Recruiting | A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer Advanced Biliary Tract Cancer | Phase 2 | 2025-06-10 |
| Recruiting | A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Thera HER2-positive Breast Cancer | Phase 2 / Phase 3 | 2025-06-05 |
| Recruiting | A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus Systemic Lupus Erythematosus | Phase 1 | 2025-06-04 |
| Recruiting | A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasi HER2-positive Breast Cancer | Phase 3 | 2025-06-03 |
| Recruiting | A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastati HER2-low Breast Cancer | Phase 3 | 2025-05-15 |
| Recruiting | A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tu Gastrointestinal Tumor, Solid Tumor | Phase 1 | 2025-05-15 |
| Recruiting | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Ur Urothelial Carcinoma | Phase 3 | 2025-03-25 |
| Recruiting | A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis Rheumatoid Arthritis | Phase 1 | 2025-03-17 |
| Recruiting | A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients Wit Non-small Cell Lung Cancer | Phase 3 | 2025-02-24 |
| Recruiting | A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors Solid Tumor | Phase 1 | 2025-02-12 |
| Active Not Recruiting | A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma Chordoma | Phase 2 | 2025-01-16 |
| Recruiting | A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies Relapsed or Refractory Lymphoid Malignancies | Phase 1 | 2025-01-02 |
| Not Yet Recruiting | A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tum Gastrointestinal Tumors, Solid Tumor | Phase 1 | 2025-01-01 |
| Recruiting | A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-posi HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | 2024-12-24 |
| Recruiting | A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Head and Neck Squamous Cell Carcinoma | Phase 2 | 2024-11-07 |
| Recruiting | A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors Breast Cancer, Solid Tumor | Phase 1 | 2024-10-30 |
| Recruiting | A Study of BL-B01D1 in Patients With Recurrent Glioblastoma Recurrent Glioblastoma | Phase 2 | 2024-10-17 |
| Recruiting | A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Non-small Cell Lung Cancer, Solid Tumor | Phase 1 | 2024-10-16 |
| Recruiting | A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Breast Cancer, Solid Tumor | Phase 1 | 2024-08-26 |
| Recruiting | A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and O Breast Cancer, Solid Tumor | Phase 1 | 2024-08-24 |
| Active Not Recruiting | A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) Small Cell Lung Cancer | Phase 3 | 2024-08-07 |
| Recruiting | A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tum Small Cell Lung Cancer, Neuroendocrine Tumors | Phase 1 | 2024-08-02 |
| Recruiting | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metas Triple-negative Breast Cancer | Phase 2 | 2024-08-02 |
| Recruiting | A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Meta Non-small Cell Lung Cancer | Phase 2 | 2024-07-31 |
| Recruiting | A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointes Esophageal Cancer, Gastric Cancer, Pancreatic Cancer | Phase 1 | 2024-07-24 |
| Recruiting | A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors Solid Tumor | Phase 1 | 2024-07-18 |
| Recruiting | A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other S Head and Neck Squamous Cell Carcinomas, Solid Tumor | Phase 1 | 2024-06-27 |
| Recruiting | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lu Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, Solid Tumor | Phase 2 | 2024-06-25 |
| Active Not Recruiting | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advan Triple-Negative Breast Cancer | Phase 3 | 2024-06-21 |
| Recruiting | A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Local HER2-positive Breast Cancer | Phase 2 | 2024-06-19 |
| Recruiting | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer Extensive-stage Small-cell Lung Cancer | Phase 2 | 2024-06-13 |
| Recruiting | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous C Head and Neck Squamous Cell Carcinoma | Phase 2 | 2024-06-07 |
| Recruiting | A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Urothelial Carcinoma | Phase 2 | 2024-05-29 |
| Active Not Recruiting | A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic No Non-small Cell Lung Cancer | Phase 3 | 2024-05-22 |
| Active Not Recruiting | A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wi Non-small Cell Lung Cancer | Phase 3 | 2024-05-17 |
| Active Not Recruiting | A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positi HER2-positive Breast Cancer | Phase 3 | 2024-05-08 |
| Recruiting | A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer Non-small Cell Lung Cancer | Phase 1 / Phase 2 | 2024-04-24 |
| Active Not Recruiting | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advan HR+HER2- Breast Cancer | Phase 3 | 2024-04-24 |
| Recruiting | A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors Locally Advanced or Metastatic Solid Tumors | Phase 1 | 2024-04-19 |
| Active Not Recruiting | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Es Esophageal Squamous Cell Carcinoma | Phase 3 | 2024-03-19 |
| Recruiting | A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies Gynecological Malignancies | Phase 1 / Phase 2 | 2024-02-29 |
| Recruiting | A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Ca Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma | Phase 2 | 2024-01-29 |
| Recruiting | A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-p Her2-positive/Low-expression Urinary and Digestive Tract Tumors | Phase 1 / Phase 2 | 2024-01-19 |
| Recruiting | A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic Breast Cancer | Phase 2 | 2023-12-12 |
| Recruiting | A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma a Urothelial Carcinoma, Solid Tumor | Phase 2 | 2023-12-11 |
| Active Not Recruiting | A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Na Nasopharyngeal Carcinoma | Phase 3 | 2023-12-04 |
| Recruiting | A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced o Esophageal Cancer, Gastric Cancer, Colorectal Cancer | Phase 2 | 2023-11-16 |
| Recruiting | A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer Small Cell Lung Cancer | Phase 2 | 2023-11-10 |
| Recruiting | A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Cervical Cancer | Phase 2 | 2023-11-06 |
| Recruiting | A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies Non-hodgkin's Lymphoma | Phase 1 / Phase 2 | 2023-11-01 |
| Recruiting | A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lun Non-small Cell Lung Cancer | Phase 1 / Phase 2 | 2023-10-30 |
| Recruiting | A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squam Head and Neck Squamous Cell Carcinoma | Phase 2 | 2023-10-20 |
| Active Not Recruiting | A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Non-small Cell Lung Cancer | Phase 1 / Phase 2 | 2023-09-04 |
| Active Not Recruiting | A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies Relapsed/Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | 2023-08-16 |
| Recruiting | A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | Phase 1 | 2023-08-02 |
| Active Not Recruiting | A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Adv Non-small Cell Lung Cancer | Phase 2 | 2023-07-19 |
| Active Not Recruiting | A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung | Phase 3 | 2023-07-14 |
| Recruiting | A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Ma Gynecological Malignant Tumor, Solid Tumor | Phase 1 / Phase 2 | 2023-06-25 |
| Recruiting | A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary S Urinary System Tumor, Solid Tumor | Phase 2 | 2023-04-20 |
| Active Not Recruiting | A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL NK/T Cell Lymphoma, Vascular Immunomother T Cell Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | 2023-02-21 |
| Recruiting | A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamou Squamous Cell Carcinoma of Head and Neck | Phase 1 / Phase 2 | 2023-02-10 |
| Active Not Recruiting | A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Re Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma | Phase 1 / Phase 2 | 2023-02-10 |
| Recruiting | Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tu Locally Advanced or Metastatic Digestive Tract Tumors, Other Solid Tumors | Phase 1 | 2023-01-05 |
| Recruiting | A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Non-hodgkin's Lymphoma | Phase 1 / Phase 2 | 2022-09-26 |
| Recruiting | A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Breast Cancer, Solid Tumor | Phase 1 | 2022-08-11 |
| Active Not Recruiting | A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | 2022-08-10 |
| Recruiting | A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer Breast Cancer, Locally Advanced or Metastatic Solid Tumor | Phase 1 | 2022-08-09 |
| Active Not Recruiting | A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tum Locally Advanced or Metastatic Digestive Tract Tumors, Solid Tumor | Phase 1 | 2022-06-01 |
| Active Not Recruiting | A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Sol Breast Cancer | Phase 1 | 2022-05-20 |
| Active Not Recruiting | A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors | Phase 1 | 2022-02-15 |
| Recruiting | A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tum Gastrointestinal Tumor | Phase 1 | 2022-02-14 |
| Active Not Recruiting | A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy Hematologic Malignancies | Phase 1 | 2022-02-09 |
| Active Not Recruiting | SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lun Non-small Cell Lung Cancer | Phase 2 / Phase 3 | 2022-01-06 |
| Active Not Recruiting | A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC Head and Neck Squamous Cell Carcinoma | Phase 2 | 2021-12-22 |
| Active Not Recruiting | SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma. Esophageal Squamous Cell Carcinomas | Phase 2 | 2021-12-13 |
| Active Not Recruiting | SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC. Non Small Cell Lung Cancer | Phase 2 | 2021-12-07 |
| Terminated | SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancie Colorectal Cancer | Phase 2 | 2021-11-30 |
| Recruiting | A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor Locally Advanced or Metastatic Solid Tumor | Phase 1 | 2021-11-29 |
| Active Not Recruiting | A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Canc Breast Cancer | Phase 1 | 2021-11-26 |
| Active Not Recruiting | A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic H Head and Neck Squamous Cell Carcinoma | Phase 2 | 2021-10-20 |
| Withdrawn | A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumor Breast Cancer, Solid Tumor | Phase 1 | 2021-09-15 |
| Recruiting | A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tu Recurrent Glioma, Solid Tumor | Phase 1 | 2021-04-14 |
| Completed | A Study of SI-F019 in Healthy Participants Healthy | Phase 1 | 2021-03-30 |
| Active Not Recruiting | A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors Solid Tumor | Phase 1 | 2020-11-10 |
| Active Not Recruiting | Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia | Phase 1 | 2020-11-04 |
| Active Not Recruiting | A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors Locally Advanced or Metastatic Epithelial Tumor | Phase 1 | 2020-04-17 |
| Unknown | Post-marketing Registration Study of Nifekalant Hydrochloride (NIF) Injection Ventricular Tachycardia, Ventricular Fibrillation | — | 2019-02-18 |
| Unknown | Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection. Ventricular Tachycardia, Ventricular Fibrillation | Phase 4 | 2019-01-15 |